Objective: To compare the effect of folic acid (FA) and a-naphthoflavone on 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced cleft palate in fetal mice.
conditions, mice exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) during organogenesis caused cleft palate (Yoon et al., 2000) . TCDD alters gene expression by activating aryl hydrocarbon receptor (AHR) that exerts important physiological functions (Willey et al., 1998) . However, there is no effective intervention to prevent cleft palate. Previous studies in mice and dogs reported the protective effect of folic acid (FA) supplementation on CLP occurrence (Domosławska et al., 2013) , but its effect on CLP recurrence is still controversial (Wehby et al., 2013) . A previous study demonstrated that FA supplementation during pregnancy reduces the incidence of TCDD-induced cleft palate in fetal mice (Li et al., 2010) . Moreover, anaphthoflavone, an AHR antagonist, has been found to reduce the incidence and severity of TCDD-induced fetal defects in mice, including cleft palate (Jang et al., 2007) . Therefore, we hypothesized that FA and a-naphthoflavone would antagonize TCDD-induced cleft palate in fetal mice. In the present study, we investigated the effect of different doses of FA and a-naphthoflavone on TCDD-induced cleft palate in fetal mice, examining the expression of GDP dissociation inhibitor (GDI) in fetal mice palate.
MATERIALS AND METHODS

Animals and Chemicals
Eight-to 10-week-old C57BL/6J mice were obtained from the experimental animal center of Chongqing Medical University and received the institutional review board approval of Chongqing Medical University, as well as treated in accordance with the Guide for the Care and Use of Laboratory Animals, published by the U.S. National Institutes of Health. Mice were housed under controlled conditions (24 6 18C, 55 6 5% humidity, 12-hour light/dark cycles, and ad libitum food and water). After 1 week of acclimation, three female mice were housed with one male mouse in a cage overnight and checked for vaginal plugs the next morning. After confirming pregnancy, that day was designated as gestation day 0 (GD 0).
TCDD, FA, a-naphthoflavone, and corn oil were purchased from Sigma-Aldrich (St. Louis, MO). Carboxymethyl cellulose was purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). TCDD was dissolved in corn oil and formulated to 4 lg/ml, while a-naphthoflavone was diluted with 0.05% carboxymethyl cellulose and formulated to 1 mg/ml and 10 lg/ml.
Animal Treatment
Pregnant mice were randomly assigned into seven groups, with eight mice in each group (n ¼ 8). The mice treated with corn oil were used as a negative control. The mice in the other six groups were given a single dose of 28 lg/kg TCDD on GD 10 by gavage. For FA treatment, TCDD-treated mice were also dosed with 5, 10, and 15 mg/kg FA on GD 10, while for anaphthoflavone treatment, the mice received a single dose of 50 lg/kg or 5 mg/kg a-naphthoflavone on GD 10. Pregnant mice were sacrificed by cervical dislocation on GD 17.5, and the embryos were harvested for further analysis. The palate was quickly removed from each embryo and stored at À808C for molecular analysis or fixed in 4% paraformaldehyde overnight for histological analysis. The body weight of pregnant mice and fetal mice was measured, and the number of live and dead fetal mice, with or without embryonic and fetal resorption, with or without cleft palate, and other malformations were recorded.
In a second study, based on the protective effect of different doses of FA and a-naphthoflavone on TCDDinduced cleft palate, 12 pregnant mice were divided into four groups, with three mice in each group (n ¼ 3): negative control, TCDD, 10 mg/kg FA þ TCDD, and 5 mg/kg a-naphthoflavone þ TCDD. On GD 13.5, GD 14.5, and GD 15.5, fresh palates were examined by light microscopy. All mice were sacrificed on GD 15.5 by cervical dislocation. Palates were isolated and split into two parts. One part was stored at À808C for molecular analysis, while the other part was washed in 0.01 M phosphate-buffered saline (PBS), fixed in 2.5% glutaraldehyde, dehydrated with gradient acetone, dried by refrigeration, the samples coated with metal, and imaged by scanning electron microscope (SEM).
Histological Examination
Fixed palates were dehydrated through ethanol, embedded in paraffin, and cut into 4-lm sections. The palate sections were stained with hematoxylin and eosin (HE) and examined under light microscopy.
Immunohistochemistry
Palate sections from GD 15.5 were examined by immunohistochemistry. Briefly, the sections were incubated with a specific rabbit monoclonal antibody for Rho GDI (Epitomics, Burlingame, CA) at a dilution of 1:90, overnight at 48C. The sections were washed with PBS and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (Zhongshan Jinqiao, Beijing, China) at 1:500 dilution in 0.01M PBS for 10 minutes at room temperature. 3,3 0 -diaminobenzidine (DAB) was used to identify positive target protein expression. Sections were counterstained with hematoxylin and mounted for observation under light microscopy.
Data Analyses
The data were expressed as mean 6 standard deviation (SD) and analyzed by SPSS 17.0 statistical software (IBM, Armonk, NY). T-test and one-way ANOVA were used to compare the difference between two and multiple groups, respectively. Chi-squared test was used to compare the sample rate. P , .05 indicates statistical significance.
RESULTS
Effects of TCDD, FA and a-Naphthoflavone on Pregnant and Fetal Mice
The appearance, feeding, drinking, and activity of pregnant mice in all groups were not affected by TCDD, FA, or a-naphthoflavone treatment. Moreover, there were no significant differences in body weight gain of pregnant and live fetal mice, average number of fetuses per litter, or the number of live fetuses per litter among the seven groups (P . .05, Table 1 ).
The incidence of cleft palate in fetal mice is shown in Table 2 . No cleft palate was found in fetal mice in the control group, while the incidence of cleft palate in the TCDD-treated group was 92.86%. FA treatment at three different doses reduced the incidence of cleft palate in TCDD-treated mice, and the effect was significant at 10 mg/kg FA (P , .05). Similarly, a-naphthoflavone treatment significantly reduced the incidence of cleft palate TCDD-treated mice to 65.52% (5 mg/kg anaphthoflavone) and 74.00% (50 lg/kg a-naphthoflavone) (P , .05), but no significant difference was observed between these two groups. Furthermore, there was no significant difference in the incidence of cleft palate between 10 mg/kg FA and two doses of anaphthoflavone treatments (P . .05, Table 2 ).
Morphological and Histological Observations of Palatal Development
On GD 13.5, palatine process in fetal mice was observed and showed a large gap in the middle, but no significant difference was found between the control and TCDD-treated groups (Fig. 1) . On GD 14.5, the gap started to disappear in the control group while a gap remained in the palate of animals in the TCDD-treated group (Fig. 1) . On GD 15.5, the palate was formed completely in the control group, but the palate gap was present in the TCDD-treated group (Fig. 1) . According to the histological staining, the palate grew vertically along the tongue on GD 13.5 in the control and TCDDtreated groups. On GD 14.5, the palatal shelves raised and formed the palatal midline in the control group, while the palate was still in the vertical position in the TCDD-treated group. On GD 15.5, the palate fused with opposite side and formed a complete palate in the control group, but the palatine process did not integrate and showed a midline opening in the TCDD-treated group (Fig. 1) .
According to SEM data, on GD 14.5, the palatine process started to fuse and integrate, and a large number of filopodia were observed on the medial edge epithelia (MEE) surface in the control group. In contrast, the palate was small, MEE was shrunken and fractured, and cell shedding legacy depression and no apparent filopodia were observed in the TCDD-treated group (Fig. 2) . In the FA-treated group, MEE was smooth and fully expanded, and visible filopodia-like structures were observed on the surface, although their numbers were less and the lengths were shorter compared with the control group. In the a-naphthoflavone-treated group, MEE was fully expanded and closely connected. Similar to the control group, a large number of filopodia were observed on MEE surface (Fig. 2) . Though appropriate doses of FA and a-naphthoflavone could significantly reduce but not completely prevent the incidence of TCDD-induced cleft palate (Table 2) ; compared with TCDD-treated group, the width of cleft palate in the FA-and a-naphthoflavone-treated groups was obviously reduced (Fig. 2) .
Effect of TCDD, FA, and a-Naphthoflavone on the Expression of GDI Protein in the Palate
We examined the expression of Rho GDI protein by immunohistochemistry. In the control group, Rho GDI was highly expressed in the palatal cells. However, TCDD treatment completely suppressed the expression of GDI protein in the palate. Interestingly, both FA and a-naphthoflavone could promote the integration of palatal cells and antagonize TCDD-induced cleft palate but failed to reverse the expression of Rho GDI protein in TCDD-treated fetal mice (Fig. 3) .
DISCUSSION
The occurrence and development of palate, including palatine vertical growth, elevation, exposure, and fusion is a complex biological process. This process is affected by genetic and/or environmental factors. In mice, the lateral palate starts to grow along the vertical side of the tongue on GD 12.5 to 14, forms MEE, and fuses to form midline epithelial seam (MES) on GD 14.5 to 15 (Cuervo and Covarrubias, 2004; Gritli-Linde, 2007) . Finally, primary palate and nasal septum are fully integrated to form a complete palate (Yamada et al., 2006) . The association between the increased risk of oral cleft and exposure to dioxin-like chemicals during pregnancy has been established in mice (Leite et al., 2002) . TCDD, a toxic component in dioxin, has been demonstrated to cause a wide spectrum of biological and toxicological responses, including reproductive and developmental defects (Hurst et al., 2002) . TCDD injection into pregnant females repro-FIGURE 1 Effect of TCDD on morphological and histological changes in the palatal development. represents palatal gap; Z represents palatal midline; P: palate; * represents palatine process; T ¼ tongue. Anatomy (320) and histology (HE340) of palate in the control and TCDD groups on GD13.5, 14.5, and 15.5.
ducibly induces cleft palate in fetuses and causes many morphological and molecular changes in MEE cells (Fujiwara et al., 2008) . However, the exact mechanism of TCDD-induced cleft palate is not clear.
Previous studies have demonstrated that the teratogenicity of TCDD is associated with the AHR signaling pathway and induces the expression of related genes, such as CYP1A1, CYP1A2, CYP1B1, and cyclooxygenase 2 (Linden et al., 2010; Yamada et al., 2014) . Here we also observed that TCDD (28 mg/kg) successfully induced cleft palate in fetal mice, and this is supported by the SEM data that showed disruption of MEE and inhibition of filopodia formation upon TCDD treatment. These data are consistent with the previous literature (Thomae et al., 2005; Yamada et al., 2014) and suggest that TCDD-induced cleft palate may be associated with disruption of the integrity of epithelium. Interestingly, Weinzweig et al. (1999) successfully established of a congenital model of cleft palate in the goat through gavaging twice daily during gestational days 32 through 41 with a plant slurry of Nicotiana glauca containing the piperidine alkaloid teratogen anabasine, these clefts were morphologically similar to human clefts. However, TCDD induced only a gap or cleft of the palates rather than a complete or incomplete cleft as occurs in humans; the difference may be related to the function of AHR signaling pathway in palate development.
Currently, a variety of vitamins and AHR antagonists have been found to play roles in preventing or reducing the occurrence of congenital malformations, including cleft lip and palate (Jang et al., 2007; Li et al., 2012) . There is still controversy with regard to the efficacy of maternal FA supplementation in the prevention of offspring orofacial cleft (Lowry et al., 2014) . Previous studies reported that FA can partially antagonize cleft palate induced by procarbazine, retinoic acid, and TCDD (Malek et al., 2004; Li et al., 2010; Yao et al., 2011) . In this study, we also observed that FA (10 mg/kg) could significantly antagonize but not completely rescue TCDD-induced cleft palate in fetal mice, but MEE filopodia were short and small, indicating that the effect of FA is not sufficient to rescue the defected structure of MEE and palatal cleft induced by TCDD.
The AHR antagonist, a-naphthoflavone, can significantly reduce but not completely inhibit the incidence and severity of fetal malformations caused by TCDD exposure in utero in mice (Jang et al., 2007) . In this study, we found anaphthoflavone treatment at 5 mg/kg (high-dose) and 50 lg/kg (low-dose) significantly reduced the incidence of cleft palate in TCDD-treated fetal mice. Neither of these two doses showed any significant toxic effects on growth and development of pregnant and fetal mice, and the antagonistic response was dose-dependent. Moreover, the SEM image of palate ultrastructure of the a-naphthoflavonetreated group was similar to that of the control group, suggesting that a-naphthoflavone can restore the palate in TCDD-treated fetus to its normal state. The ameliorating effect of FA and a-naphthoflavone on reducing cleft palate has been reported, but this study is the first to compare their effects at different doses. Although no significant difference was found between the two chemicals, compared with FA, 5 mg/kg a-naphthoflavone showed a moderately stronger attenuation of TCDD-induced cleft palate.
Rho GTP enzymes play a variety of biological functions, including cell cycle progression, cell morphology and movement, phagocytosis, apoptosis, and substance-transport, by modulating the activity of their downstream effector proteins. Rho GDIs can recognize Rho GTP on the cell membrane and protect GTP enzymes from degradation by apoptotic proteases (Zhang and Zhang, 2006) . Here, we observed high expression of Rho GDP GDI in normal palatal tissue, and its expression in the palate was completely inhibited by TCDD treatment. Thus, we speculate that Rho GDIs may positively regulate and stimulate Rho GTP enzyme activity in palatal tissue, as well as mediate the formation of a complete palate. However, this hypothesis warrants further investigation. The inhibited expression of GDI in TCDD-treated mice was not rescued by FA or a-naphthoflavone treatment. Interestingly, both FA and a-naphthoflavone could promote the integration of palatal cells and antagonize TCDD-induced cleft palate but failed to reverse the expression of Rho GDI in TCDD-treated fetal mice. The mechanism behind these observations needs further investigation.
The movement of MEE is the prerequisite of palatal fusion, and the filopodia of MEE surface plays a key role in this process (Cuervo and Covarrubias, 2004) . The effect of TCDD on MEE is associated with the occurrence of cleft palate. Here, we speculate that TCDD may activate oxidative stress, induce MEE apoptosis, reduce the formation of filopodia and MEE motility, and thus inhibit palatal fusion and cause cleft palate. The main active form of FA in vivo is 5-methyltetrahydrofolate, which and exhibits antioxidant effects. An AHR antagonist and inhibitor for CYP1A1 and CYP1A2 is a-naphthoflavone (Tutel'yan et al., 2003) , which exhibits antioxidant and scavenging oxygen radical effects. Therefore, FA and anaphthoflavone may reduce the generation of reactive oxygen species, inhibit MEE apoptosis through antioxidation, and increase filopodia and MEE movement. This may result in restoration of the ultrastructure of the palatal surface to a normal state, leading to the fusion and formation of complete palate in TCDD-treated fetal mice. However, the precise mechanisms of the protective effect of FA and a-naphthoflavone on TCDD-induced cleft palate still need further investigation.
